| GOL | PBO-NE | PBO-EE |
---|
Number of patients | 287 | 99 | 50 |
Female (%) | 231 (0.8) | 72 (0.73) | 41 (0.82) |
Age (SD) | 51.92 (11.94) | 52.77 (11.17) | 49.24 (11.84) |
Disease duration (SD) | 7.19 (6.82) | 7.64 (8.16) | 6.56 (6.06) |
BMI (SD) | 27.19 (5.74) | 26.88 (5.36) | 26.73 (6.65) |
Initial DAS (SD) | 5.97 (0.81) | 5.87 (1.02) | 5.93 (0.8) |
RF positive (%) | 265 (0.92) | 91 (0.92) | 45 (0.9) |
ACPA positive (%) | 262 (0.91) | 92 (0.93) | 48 (0.96) |
Number of visits (SD) | 15.03 (2.7) | 14.65 (3.18) | 15.76 (0.72) |
Number removed (%) a
| 5 (2) | 10 (10) | 0 (0) |
- GOL includes patients randomized to GOL treatment at week 0. PBO-NE includes patients randomized to PBO at week 0 who did not qualify for the early escape protocol. PBO-EE includes patients randomized to PBO at week 0 who qualified for the early escape protocol
-
ACPA anti-citrulinated peptide antibody, BMI body mass index, DAS Disease Activity Score, EE early escape, GOL golimumab, NE non-early escape, PBO placebo, RF rheumatoid factor, SD standard deviation
-
aPatients from any arm who dropped out within 4 weeks of initial GOL treatment were removed from analyses